Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156896 | 0.92 | MEN1 (0.40) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL755490 | 0.81 | MEN1 (0.54) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL24183215 | 0.79 | FNTA (0.54) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL3740198 | 0.78 | MEN1 (0.49) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL17513155 | 0.78 | ALDH1A1 (0.55) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL15335413 | 0.77 | MEN1 (0.49) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL12501801 | 0.76 | FNTA (0.51) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL12501800 | 0.76 | FNTA (0.51) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL755261 | 0.76 | MEN1 (0.50) | MEN1KMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL3740202 | 0.76 | MEN1 (0.50) | MEN1KMT2AFNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260101926-A1 | VAPORIZING DEVICE | MINSKOFF NOAH MARK (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | ALKALAY RACHEL (IL) | 2024-11-28 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240226218-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | Novel Concepts Medical Ltd (IL) | 2024-07-11 | — | — | US | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230293480-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-11684604-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230181665-A1 | TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES MELLITUS 10 TYPE I AND TYPE II AND THYROID DISEASES | Novel Concepts Medical Ltd (IL) | 2023-06-15 | — | — | US | disclosed |
| US-20230134432-A1 | COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES | Novel Concepts Medical Ltd (IL) | 2023-05-04 | — | — | US | disclosed |
| US-20220387537-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2022-12-08 | — | — | US | disclosed |
| US-10005947-B2 | Modified hydrocarbon resins as fluid loss additives | INGEVITY SOUTH CAROLINA, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3071782-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | Georgia-Pacific Chemicals LLC (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077215-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | GEORGIA-PACIFIC CHEMICALS LLC (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150136402-A1 | MODIFIED HYDROCARBON RESINS AS FLUID LOSS ADDITIVES | GEORGIA-PACIFIC CHEMICALS LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-4433100-A | DICYCLOPENTADIENE, NON-AROMATIC UNSATURATED HYDROCARBON, FATTY OR ROSIN ACID | NEVILLE CHEMICAL COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260101926-A1 | VAPORIZING DEVICE | SARAF, HSF1, TFPI | MEN1 2233/4885KMT2A 4843/4885FNTA 478/4885 |
| US-11684604-B2 | Cannabis based therapeutic and method of use | CNR2, CNR1, OPRK1 | MEN1 4877/4885KMT2A 1207/4885FNTA 1137/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | MEN1 4858/4885KMT2A 3589/4885FNTA 359/4885 |
| US-20240390446-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES | TPO, TNF, ADAMTS13 | MEN1 287/4885KMT2A 3939/4885FNTA 1482/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | MEN1 1242/4885KMT2A 2506/4885FNTA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.